A genetically modified prokaryotic
cell comprising:at least one of the following:i. an addition, deletion and / or alteration of at least one
gene to promote to
taurine production; andii. an addition, deletion and / or alteration of at least one
gene related to
taurine cellular transportation; andat least one of the following
polynucleotide sequences:i. a vanin (vnn)
polynucleotide sequence selected from the group consisting of:vanin-1 (vnn1), wherein said vnn1
polynucleotide sequence has at least 70% sequence coverage to SEQ 3 or SEQ 98, and at least 70%
sequence identity to SEQ 3 or SEQ 98;vanin-2 (vnn2), wherein said vnn2 polynucleotide sequence has at least 70% sequence coverage to SEQ 100, and at least 70%
sequence identity to SEQ 100; andvanin-3 (vnn3), wherein said vnn3 polynucleotide sequence has at least 70% sequence coverage to SEQ 141, and at least 70%
sequence identity to SEQ 141;ii. a
cysteamine dioxygenase (ado) polynucleotide sequence which has at least 70% sequence coverage to SEQ 1, and at least 70% sequence identity to SEQ 1; andiii. a flavin-containing
monooxygenase 1 (fmo1) polynucleotide sequence which has at least 70% sequence coverage to SEQ 5 or SEQ 99, and at least 70% of sequence identity to SEQ 5 or SEQ 99.